Morgan Stanley, MUFG Support Bristol-Myers Squibb/Celgene Merger
Bristol-Myers Squibb agreed to acquire biopharmaceutical company Celgene in a $74 billion cash and stock transaction. Morgan Stanley Senior Funding and MUFG Bank will provide the debt financing to support the transaction.
January 7, 2019
Bristol-Myers Squibb | Celgene | Morgan Stanley | Morgan Stanley Senior Funding | MUFG Bank
Amanda Koprowski